Changing the Name Game with Addison Whitney’s Ari™ 

What if drug naming could be faster, smarter and more aligned to brand strategy? 

In this episode of The Syneos Health Podcast: Conversations on Commercialization, Addison Whitney's Joe Daley, President and Bill Purdy, SVP and Managing Director, break down how Ari™, a purpose-built AI platform, is solving long-standing naming and branding challenges in biopharma.  

Listen and learn: 

- How Ari™ integrates strategic input, trademark search and POCA screening 
- Ways AI reduces attrition and regulatory risk in naming 
- Why naming is now a strategic process and not just a creative one 

Like what you’re hearing? Find the full Conversations on Commercialization podcast stream here. Also available anywhere you listen to podcasts.

Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].